Manufacturing of Advanced Therapy Medicinal Products within KCC
Vecura is a production unit within KCC for advanced therapy medicinal products and cells for transplantation.
Advanced therapy medicinal products (ATMP) intended for clinical use (for use in a clinical trial or under hospital exemption) must be manufactured with permission from the Medical Products Agency and in accordance with good manufacturing practice (GMP).
Regardless of whether you come from industry, healthcare, or academia, Vecura offers a comprehensive package solution encompassing research, process development, GMP production, clinical trials, education, and consultation within GMP. They also possess cleanroom capabilities. Here you can develop tailored production processes for projects that have gone through the Single Entry Point and the prioritization council at KCC.
The operations are approved by the Medical Products Agency for the manufacture of advanced therapy medicinal products for clinical trials and hold tissue establishment permits from both the Medical Products Agency and the Health and Social Care Inspectorate (IVO) for the handling of cells and tissues.
“Much of today’s conventional drug treatments work of course by relieving symptoms, but with this the basic idea is to cure the patient. This could have far-reaching effects on healthcare as we know it,” – Pontus Blomberg, operations manager at Vecura.
